Updated Covid-19 Vaccine Targeting JN.1 Recommended By FDA Panel
An FDA panel recommended that Moderna, Pfizer-BioNTech, and Novavax should develop new Covid-19 vaccines that target the JN.1 variant of SARS-CoV-2.
An FDA panel recommended that Moderna, Pfizer-BioNTech, and Novavax should develop new Covid-19 vaccines that target the JN.1 variant of SARS-CoV-2.
What's Your Reaction?
